Combined Use of Bevacizumab + Interferon A-2 α in the Treatement of Patients with Disseminated Kidney Cancer in Comparison with an Active Monitoring Group

Introduction. Despite the fact that the combined use of bevacizumab and interferon α -2A has been studied extensively and proved to be safe, there will always remain a group of patients for whom continuing the long-term drug treatment after a radical surgery would be unfeasible through personal reasons. This paper presents a comparison of the use of bevacizumab in combination with IFN α -2A and active monitoring in patients with metastatic kidney cancer.

Materials and methods. This is a retrospective treatment outcome analysis performed on 24 patients following radical surgery. The clear cell RCC was morphologically verified following the nephrectomy in all the cases. The patients’ ages ranged from 62 to 84, averaging at 73 ± 2.2.

Results. The outcomes for patients receiving treatment and those being actively monitored were then assessed for the total of 24 people counting both groups. The average length of time without progression amounted to 12.9 months and 9.8 months in the groups A and B, respectively. The median overall survival rate amounted to 22.3 and 18.7 months in the groups A and B, respectively.

Discussion. The results demonstrate rather good indicators for the group of patients with metastatic kidney cancer receiving no drug therapy in comparison with the group receiving treatment in accordance with the classic immunotherapy protocol. No significant or fundamental differences have been observed when the groups studied were compared.

Conclusion. A competent case-specific approach to treatment strategies for various metastatic kidney cancer patient cohorts is important both for planning satisfactory survival rate indicators and for maintaining the quality of life suited specifically for each patient.

1. Kaprin A.D., Starinskii V.V. Petrova G.V. (editors) Malignant neoplasms in Russia in 2017: morbidity and mortality. Moscow; 2018. 250 p. (in Russ.).

2. Alekseev B.Y. Metastatic kidney cancer: choice of first-line therapy. Cancer Urology. 2014;10(3):43-8 (in Russ.). DOI: 10.17650/1726-9776-2014-10-3-43-48

3. Shinohara N., Obara W, Tatsugami K., Naito S., Kamba T., Taka-hashi M., et al. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015;106(5):618-26. DOI: 10.1111/cas.12646

4. Motzer R.J., Jonasch E., Agarwal N., Bhayani S., Bro W.P., Chang S.S., et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Kidney Cancer, Version 2.2017. J Natl Compr Canc Netw. 2017;15:804-34. DOI: 10.6004/jnccn.2017.0100

5. Powles T., Albiges L., Staehler M., Bensalah K., Dabestani S., Giles R.H., et al. Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol. 2018;73(3):311-5. DOI: 10.1016/j.eururo.2017.11.016

6. Anselmo Da Costa I., Rausch S., Kruck S., Todenhofer T., Stenzl A., Bedke J. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where will we go? Expert Rev Anticancer Ther. 2017;17(4):357-68. DOI: 10.1080/14737140.2017.1292138

7. Escudier B., Albiges L. Anti-VEGF and VEGFR monoclonal antibodies in RCC. In: Bukowski R., Figlin R.A., Motzer R. (editors). Renal cell carcinoma: molecular targets and clinical applications. Springer; 2015. P. 237-52.

8. Thomas L., Lai S.Y., Dong W, Feng L., Dadu R., Regone R.M. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist. 2014;19(3):251-8. DOI: 10.1634/theoncologist.2013-0362

9. North S.A., Basappa N., Basiuk J., Bjarnason G., Breau R., Canil Ch., et al. Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Can Urol Assoc J. 2015;9(5-6):164-70. DOI: 10.5489/cuaj.2894

10. Shen C.T., Qiu Z.L., Luo Q.Y. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer. 2014;21(2):253-61. DOI: 10.1530/ERC-13-0438

11. Soerensen A.V., Donskov F., Hermann G.G., Jensen N.V., Petersen A., Spliid H., et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. Eur J Cancer. 2014;50 (3):553-62. DOI: 10.1016/j.ejca.2013.10.010

12. Godo S., Yoshida Y., Kawamorita N., Mitsuzuka K., Kawazoe Y., Fujita M., et al. Life-threatening hyperkalemia associated with axitinib treatment in patients with recurrent renal carcinoma. Intern Med. 2018;57(19):2895-900. DOI: 10.2169/internalmedicine.0262-17

13. Powles T., Rini B. Novel agents and drug development needs in advanced clear cell renal cancer. J Clin Oncol. 2018 Oct 29:JCO2018792655. DOI: 10.1200/JCO.2018.79.2655

14. Dorff T.B., Longmate J.A., Pal S.K., Stadler W.M., Fishman M.N., Vaishampayan U.N., et al. Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 2017;123(23):4566-73. DOI: 10.1002/cncr.30942

15. Davis I.D., Xie W., Pezaro C., Donskov F., Wells J.C., Agarwal N., et al. Efficacy of second-line targeted therapy for renal cell carcinoma according to change from baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol. 2017;71(6):970-8. DOI: 10.1016/j.eururo.2016.09.047